ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2234

Targeting Therapy Of Citrullinated Antigen-Specific B Cells Ameliorates Collagen-Induced Arthritis

Kazuya Michishita1, Kimito Kawahata1, Takeyuki Kanzaki2, Lisa Akahira1, Toshiki Eri1 and Kazuhiko Yamamoto3, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Internal Medicine, Yamanashi Prefectural Central Hospital, Yamanashi, Japan, 3Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: animal models and treatment, B cell targeting, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The clinical benefit of B-cell depletion therapy in rheumatoid arthritis(RA) is a well-known fact, but problems such as relapse of tuberculosis and reactivation of hepatitis B are reported.We thought that these problems were resolved by focusing on depletion of pathogenic antigen-specific B cells using a B cell epitope tetramer conjugated with immunotoxin. We treated collagen-induced arthritis (CIA) mice by the peptide-tetramer method.

Methods:

Arthritis was induced by immunizing DBA/1J mice with Bovine Type II collagen. Toxin-conjugated peptide tetramers, which had the ability to deplete peptide-specific B cells, were intravenously administered to CIA mice. After first immunization (day0), tetramers were administrated in day10 and day20 and boost immunization was carried out in day 21.We used three kinds of peptides for preparing tetramers. One (CIA1), which has citrullinated arginine residue of C1 domain, is a major epitope of type II collagen. The second (CIAC) has non-citrullinated arginine residue of C1 domain. The third has the lysine residue-rich peptide (LKP) as a control. We conjugated immunotoxin to these peptide tetramers in order to deplete peptide-specific B cells. We chose saporin which was class I ribosome-inactivating proteins as a immunotoxin. Non-cytotoxic tetramer using CIA1, anti-CD20 antibody, the anti-CD79β antibody and PBS were also injected mice as a comparison. The incidence, arthritis score and antibodies to peptide were evaluated.

Results:

In mice administered CIA1 tetramer, anti-CIA antibody completely dissapeared as compared with PBS group (P = 0.01) and the onset of arthritis was delayed. Because the antibody titers for U1 epitope of the type II collagen did not have the significant difference between CIA1 and PBS group, it was shown that we depleted the B cells which were an antigen-specific. In mice administered tetramers using CIAC or LKP, anti-CD20 antibody, antiCD79 antibody and non-cytotoxic tetramer using CIA1, the antibody titers for CIA1 have increased and the onset of the arthritis was delayed.

Conclusion:

By the depletion of citrullinated antigen-specific B cells using a B cell-epitope tetramer, the onset of the arthritis was delayed. It was necessary for the tetramer to have the cytotoxicity and the citrullinated peptide in order to improve clinical and pathological score. Targeting of citrullinated antigen-specific B cells might be a new strategy of RA treatment.


Disclosure:

K. Michishita,
None;

K. Kawahata,
None;

T. Kanzaki,
None;

L. Akahira,
None;

T. Eri,
None;

K. Yamamoto,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/targeting-therapy-of-citrullinated-antigen-specific-b-cells-ameliorates-collagen-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology